NeuroMetrix Launches Website for SENSUS™ Pain Management System

  NeuroMetrix Launches Website for SENSUS™ Pain Management System

Business Wire

WALTHAM, Mass. -- January 30, 2013

NeuroMetrix, Inc. (Nasdaq: NURO),, a medical device
company focused on the diagnosis and treatment of the neurological
complications of diabetes, announced that is has launched a website
( for the SENSUS Pain Management System. The
website provides patients, physicians and durable medical equipment (DME)
suppliers with a one-stop Internet portal for SENSUS information and support

SENSUS is a transcutaneous electrical nerve stimulator intended for the
symptomatic relief and management of chronic intractable pain in the lower
legs and feet. It offers physicians and their patients advanced medical
technology in a light weight, low profile device worn on the upper calf that
is activated by the press of a single button. The Company’s marketing efforts
for SENSUS are targeted at patients with diabetes who suffer from chronic
pain, most commonly due to painful diabetic neuropathy. It is partnering with
a growing network of DME suppliers responsible for physician detailing,
supplying product to patients, and insurance billing.

“The SENSUS website provides convenient, comprehensive product support,” said
Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer of
NeuroMetrix. “Since we launched SENSUS several weeks ago we have been
encouraged by the interest we’ve seen from physicians and patients. This new
website is a tool to reach a growing audience. It contains a wide range of
product and disease information that we intend to expand over time.”

About NeuroMetrix

NeuroMetrixis an innovative medical device company that develops and markets
home use and point-of-care devices for the treatment and management of
diabetic neuropathies, which affect over 50% of people with diabetes. If left
untreated, diabetic neuropathies trigger foot ulcers that may require
amputation, cause disabling chronic pain, and increase the risk of falling in
the elderly. The annual cost of diabetic neuropathies has been estimated
at$14 billioninthe United States. The company’s products are used by
physicians and managed care organizations to optimize patient care and reduce
healthcare costs. The company markets the NC-stat^®DPNCheck^™device, which
is a rapid, accurate, and quantitative point-of-care test for diabetic
neuropathy. This product is used to detect diabetic neuropathy at an early
stage and to guide treatment. The company also markets the SENSUS^™ Pain
Management System for treating chronic pain, focusing on physicians managing
patients with painful diabetic neuropathy. The company has additional
therapeutic products in its pipeline. For more information, please visit


NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
Press spacebar to pause and continue. Press esc to stop.